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by the production and progressive accumulation of a fibrillar
extracellular material in many ocular tissues [1]. It is now
understood to be the most common identifiable cause of open-
angle glaucoma worldwide, accounting for the majority of
cases  of  this  disease  in  some  countries  [2].  Its  incidence
increases  progressively  with  age  while  its  widespread
distribution, its frequency, and its potential association with
other diseases is only beginning to be realized.
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Purpose: To evaluate genetic susceptibility of lysyl oxidase-like 1 (LOXL1) gene polymorphisms to exfoliation syndrome
(XFS) and exfoliation glaucoma (XFG) in a case-control cohort of American and European patients.
Methods: DNA from a total of 620 individuals including 287 exfoliation patients and 333 healthy control subjects were
extracted by standard methods. Three single nucleotide polymorphisms (SNPs) of rs1048661 (R141L), rs3825942
(G153D), and rs2165241 were genotyped in these individuals by SNaPshot Assay. The seven coding exons of the
LOXL1 gene and their immediate flanking regions were directly sequenced in 95 affected patients. Data management and
case-control association studies were performed with SNP-STAT and PLINK programs. The obtained DNA sequences
were evaluated with the STADEN package.
Results: The 287 unrelated exfoliation cases comprised of 171 American patients (mostly of European background) and
116 patients from 12 European countries. This phenotype was further divided into patients with exfoliation only and no
glaucoma (XFO; n=95), exfoliation with glaucoma (XFG; n=133), and exfoliation unclassified (XFU; n=59). Genotypic
data were analyzed separately for XFO, XFG, XFU, and XFS (all exfoliations; n=287) and for Americans and Europeans.
The observed genotypic frequencies for each exfoliation phenotype or population were tabulated separately and tested for
deviation from the Hardy–Weinberg equilibrium (HWE) using a standard Χ2 test. There were no HWE deviations and no
significant genotypic differences between these subcategories for the three studied SNPs. For the combined exfoliation
cohort,  homozygote  genotypes  of  G/G  (rs1048661),  G/G  (rs3825942),  and  T/T  (rs2165241)  were  significantly
overrepresented. Likewise, case-control allelic association for rs1048661 (p=7.74x10−9), rs3825942 (p=3.10x10−17), and
rs2165241  (p=4.85x10−24)  were  highly  significant.  The  corresponding  two-locus  haplotype  frequencies  of  GG  for
rs1048661-rs3825942 (p=1.47x10−27), GT for rs1048661-rs2165241 (p=1.29x10−24), and GT for rs3825942-rs2165241
(p=2.02x10−24) were highly associated with exfoliation phenotypes. The combined effect of these three SNPs revealed
that the GGT haplotype is overrepresented by 66% in exfoliation cases, and this deviation from controls is highly significant
(p=1.93x10−24). This haplotype constituted a major risk factor for development of exfoliation in both XFS and XFG. By
contrast, the GAC haplotype was significantly underrepresented (p=4.99x10−18) in exfoliation cases by 83% and may
potentially have a protective effect for this condition with an estimated attributable risk percent reduction of 457%. The
only other haplotype that was significantly different between cases and controls was TGC (p=5.82x10−9). No observation
was made for the GAT haplotype. The combined three haplotypes of GGT, GAC, and TGC were associated with 91% of
the exfoliation syndrome cases in the studied populations. Seven coding exons of LOXL1 were also sequenced in 95
affected cases. In addition to the three above-mentioned SNPs, 12 other variations were also observed in these patients
(G240G,  D292D,  A320A,  V385V,  rs2304719,  IVS3+23C>T,  IVS3–155G>A,  IVS3–101G>A,  IVS4+49G>A,
rs2304721, IVS5–121C>T, and rs2304722). None were considered a disease-causing mutation.
Conclusions: We confirmed a strong association with LOXL1 variants in our patients. For the LOXL1 gene, individual
alleles of rs1048661 (G), rs3825942 (G), and rs2165241 (T) are highly associated with XFS and XFG in American and
European populations. The GGT haplotype constitutes a major risk haplotype for exfoliation, and GAC may have a
protective role. DNA sequencing of 95 affected patients did not show any mutations in this gene. The LOXL1 SNPs are
located in the 15q24.1 band and within a genetic locus (GLC1N) that is associated with primary open-angle glaucoma
(POAG). However, the LOXL1 genetic predisposition is only limited to exfoliation with or without glaucoma and does
not include the POAG phenotype.All  anterior  segment  structures  are  involved  in  XFS.
Deposits of white material on the anterior lens surface are the
most consistent and important diagnostic feature. The classic
pattern consists of three distinct zones that become visible
when the pupil is fully dilated, a central disc, an intermediate
clear zone created by the iris rubbing exfoliation material from
the  lens  surface  during  its  physiologic  excursions,  and  a
granular peripheral zone [1]. Exfoliation material is often
found at the pupillary border.
Exfoliation  material  is  a  complex  glycoprotein/
proteoglycan  structure  bearing  epitopes  of  the  basement
membrane and elastic fiber system. The characteristic fibrils,
which are composed of microfibrillar subunits surrounded by
an amorphous matrix comprising various glycoconjugates,
contain  predominantly  epitopes  of  elastic  fibers  such  as
elastin, tropoelastin, amyloid P, vitronectin, and components
of  elastic  microfibrils  such  as  fibrillin-1,  microfibril-
associated  glycoprotein-1,  and  latent  transforming  growth
factor  beta-binding  proteins  (LTBP1  and  LTBP2)  by
immunohistochemistry [1,3].
The risk of developing glaucoma is 5–10 times more
common in eyes with XFS than in those without it. About 25%
of patients with XFS have elevated intraocular pressure (IOP),
and one-third of these have glaucoma. Patients with XFS are
twice  as  likely  to  convert  from  ocular  hypertension  to
glaucoma, and when glaucoma is present, it progresses more
rapidly [4-6].
Exfoliation syndrome leads not only to severe, chronic
open-angle glaucoma but may also lead to lens subluxation,
angle-closure, blood-aqueous barrier impairment, and serious
complications at the time of cataract extraction such as zonular
dialysis,  capsular  rupture,  and  vitreous  loss.  There  is
increasing evidence for an etiological association of XFS with
cataract formation and with retinal vein occlusion. Deposits
of exfoliation material have been found in the heart, lung,
liver, kidney, gall bladder, and cerebral meninges by electron
microscopy [7,8].
An  increasing  number  of  associations  with  specific
systemic  disorders,  primarily  related  to  vasculopathy,  has
been  reported  including  transient  ischemic  attacks  [9],
hypertension,  angina,  myocardial  infarction,  stroke,
asymptomatic  myocardial  dysfunction  [10],  Alzheimer
disease [11-13], and hearing loss [14,15].
Exfoliation  syndrome  is  seemingly  inherited  as  an
autosomal dominant condition as evidenced by the largest
available pedigree described in Nova Scotia [16]. Although,
mitochondrial and even multifactorial modes of inheritance
have also been suggested for XFS [17], familial cosegregation
has  been  observed  in  many  populations.  A  genome-wide
linkage study of the Finnish population has recently identified
a promising genetic locus on 18q with a multipoint LOD score
of 4.2 as well as other potential loci on 2q, 17p, and 19q
[18].  We  also  identified  a  provisional  locus  on  the  2q36
region, but mutation screening of over 20 genes has not as yet
identified the defective molecule for XFS (unpublished data).
A recent genome-wide association study in the Icelandic
population  identified  multiple  single  nucleotide
polymorphisms (SNPs) in the lysyl oxidase-like 1 (LOXL1)
gene on 15q24.1 that are highly associated with the exfoliation
phenotype [19]. Replication studies in the Swedish population
confirmed genetic susceptibility of LOXL1 polymorphisms to
exfoliation  with  (XFG)  or  without  glaucoma  (XFS)  [19].
However, no genetic association was observed in a group of
unrelated primary open-angle glaucoma (POAG) for either of
these two populations.
In  this  study,  we  investigated  the  role  of  LOXL1
polymorphisms in 620 American and European patients (287
exfoliation and 333 controls). Our study confirmed that the
LOXL1 polymorphisms are highly associated with both XFS
and XFG patients in the two populations studied.
METHODS
Clinical diagnosis: The diagnosis of exfoliation syndrome
was made by direct visualization on a slit-lamp examination
of the typical pattern of exfoliation material on the anterior
lens surface after pupillary dilation. Exfoliative glaucoma was
diagnosed as those showing the characteristics of a history of
intraocular pressure greater than or equal to 22 mmHg and a
presence  of  typical  glaucomatous  optic  disc  cupping  and
visual field loss.
Patient population: The patient population was composed of
two major subgroups, Americans and Europeans (Table 1). A
total  of  171  American  exfoliation  cases  (93  XFG)  were
examined and clinically diagnosed by two of the authors (R.R.
and  J.L.).  All  but  five  patients  in  this  subgroup  were  of
European ancestry.
The  remaining  116  patients  (40  XFG)  were  from  12
European  countries,  primarily  Irish,  Scottish,  English,
Finnish,  or  Maltese.  Their  exfoliation  and  glaucoma
diagnoses were made by their respective ophthalmologists.
Several  of  them  were  found  to  have  additional  family
members affected with exfoliation or glaucoma in a pattern
suggesting autosomal dominant inheritance [17,20]. Many of
these  family  members  were  clinically  and  genetically
ascertained, and their DNA samples were collected. However,
TABLE 1. DISTRIBUTION OF EXFOLIATION PATIENTS WITH NO GLAUCOMA (XFO),
EXFOLIATION WITH GLAUCOMA (XFG), AND EXFOLIATION UNCLASSIFIED (XFU)
IN AMERICAN AND EUROPEAN PATIENTS.
Subtype American European Total
XFO 72 23 95
XFG 93 40 133
XFU 6 53 59
XFS 171 116 287
XFS represents all exfoliation groups combined.
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534for  this  case-control  association  study,  only  one  affected
member per family was used.
Of the 287 unrelated exfoliation patients included in this
study (Table 1), only 133 (93 Americans) were reported to
have exfoliation glaucoma (XFG). Further, 95 (72 Americans)
cases were reported to have only exfoliation (XFO) with no
glaucoma. The glaucoma status for the remaining 59 (six
Americans) unrelated patients was not reported, and thus,
these  cases  were  considered  as  unclassified  (XFU).
Altogether, 287 patients with exfoliation syndrome (XFS)
including 133 XFG were used for statistical evaluation.
Similarly,  we  used  a  group  of  333  unrelated  healthy
control subjects from the United States and Europe. To the
best of our knowledge, none of the control individuals who
participated  in  this  study  was  related  to  our  exfoliation
patients. All of these healthy controls were clinically screened
for the presence of exfoliation and glaucoma, and the majority
of them declared as having a European genetic background.
All the controls were between 60 and 98 years old and so they
were age- and ethnically-matched with our exfoliation group.
The  inclusion  of  human  subjects  in  our  study  was
approved by the University of Connecticut Health Center
Institutional Review Board.
SNaPshot genotyping assay: SNP genotyping was performed
by  the  SNaPshot  Assay.  Unmodified,  flanking
oligonucleotide primers were synthesized and the polymerase
chain  reaction  (PCR)  product  of  each  targeted  SNP  was
generated separately by standard PCR reactions as described
below. DNA samples from 620 unrelated exfoliation cases
and  controls  were  used  for  PCR  amplification  of  three
different LOXL1 SNP markers, and their PCR products were
pooled  together  separately  for  each  individual.  We  also
synthesized three other internal primers that would anneal to
sequences adjacent to the exact site of each SNP marker.
Subsequently, the pooled PCR products were subjected to a
second round of PCR amplification using the ABI-SNaPshot
Multiplex Kit and unlabeled internal primers. The new PCR
reaction extended by only one nucleotide base at the exact site
of the SNP and then terminated. The SNaPshot Multiplex Kit
contains four ddNTPs that are fluorescently labeled with a
different color dye. Since the length of our internally designed
primers differed by at least 10 base pairs (bp), the newly
generated fragments varied by size for various SNPs and by
color  for  the  allelic  polymorphism  within  each  SNP.
Therefore,  based  on  the  two  distinctive  color  and  size
differences, these multiplex PCR products were separated on
an ABI-3100 Gene Analyzer instrument, and the resultant
products were sized and genotyped by the ABI-GeneMapper
Fragment Analysis Software (version 3.5).
SNaPshot PCR reaction—Each purified PCR product
(1 μl) was added to 4 μl of a master mixture (0.5 μl SNaPshot
mix,  0.2  μl  of  each  SNaPshot  primer  [10  pmol/μl],  and
3.3 μl of deionized H2O) and subjected to a second PCR
reaction (35 cycles of 96 °C/10 s, 50 °C/5 s, and 60 °C/30 s).
The SNaPshot products were purified by the shrimp alkaline
phosphatase (SAP) treatment and then run on an ABI-3100
Gene Analyzer instrument. The genotyping of samples were
performed with the help of GeneMapper software (version
3.5).
Polymerase chain reaction: A set of primers was designed
(forward: 5′-AAG GCC AGC ATG GAC AAA GCT AGA-3’
and reverse: 3’-GTA GTA CAC GAA ACC CTG GTC GTA
GGT-5′)  to  amplify  a  751  bp  fragment  from  exon  1  of
LOXL1 that contained the two SNPs (rs1048661 [R141L] and
rs3825942  [G153D]).  A  second  primer  set  was  designed
(forward: 5′-TTC TTA GAA TGC AAG ACC TCA GC-3′
and reverse: 3′-CTC AGG GTA GTG GCC AGA GG-5′) to
amplify a 269 bp fragment from intron 1 that carried the
rs2165241 SNP. PCR reactions were performed to amplify a
specific  fragment  of  genomic  DNA  in  the  MJ  Research-
PTC-200 Peltier Thermal Cycler. The standard PCR program
was performed under the following conditions: 96 °C/2 min,
55 cycles (96 °C/30 s, 63 °C/30 s, and 72 °C/30 s), and 72 °C/
5 min final elongation. All the PCR products were checked
for  amplification  by  agarose  gel  electrophoresis  and
subsequently purified by SAP and Exo-I treatment.
DNA Sequencing: A series of oligonucleotide primers were
synthesized for amplification of seven known coding exons
of LOXL1. Each set was designed with Primer3 software and
covered at minimum 200 bp of the flanking intronic sequences
(primers are available). Exon 1 was amplified and sequenced
in  two  overlapping  fragments.  Each  exon  was  amplified
separately;  their  PCR  products  were  purified,  directly
sequenced  with  BigDye  Terminator  (version  3.1)  Cycle
Sequencing  Kit,  and  run  on  an  ABI  PRISM  3100  DNA
sequencing  instrument.  The  data  were  transformed  to  the
STADEN package, and sequences were aligned together for
each exon and for all of the 95 individuals used for this part
of our study.
Statistical analysis: The genotypic data as determined by the
SNaPshot assay were imported into an in-house SNP data
management program (SNP-STAT). The observed number of
genotypes for each SNP were counted and the genotypic and
allele  frequencies  were  tabulated  automatically.  The  two-
locus genotypic counts and frequencies were also estimated
for each set of SNP pairs. The standard Χ2 was used to test for
deviation  from  the  Hardy–Weinberg  equilibrium  and  to
compare the genotypic and allelic frequencies in exfoliation
and control groups. Odds ratios, attributable risk percents (AR
%),  population  attributable  risk  percents  (PAR%),  and  p-
values  were  calculated,  and  their  appropriate  confidence
intervals  were  computed  at  the  95%  level.  For  each  sub-
phenotype  (XFO,  XFU,  XFG,  and  XFS)  and  for  each
population  (American  and  European),  this  process  was
repeated. The SNP-STAT program was further used to export
SNP information together with the entire genotypic data for
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535use with the PLINK program [21]. All the statistical analyses
were re-evaluated by the PLINK, and in addition, this program
was used to determine the most likely haplotype-phases for
the LOXL1 SNPs and to further estimate their frequencies in
exfoliation and control groups.
RESULTS
All of 287 cases used in this study had XFS (Table 1). Subsets
had no glaucoma (XFO, n=95), glaucoma (XFG, n=133), or
remained  unclassified  (XFU,  n=59).  For  each  of  these
phenotypic subgroups and for each of the three SNPs of the
LOXL1 gene, we tabulated both genotypic and allelic counts
separately (Table 2 and Table 3) and made a cross-comparison
statistical analysis by using a standard Χ2 test. Table 2 shows
allelic  counts  and  corresponding  uncorrected  p-values  for
each of the three SNPs. Of the 18 multiple tests shown in this
table,  only  the  p-value  between  XFO  and  XFG  was
significantly different. However, if one uses the Bonferroni
correction method that multiplies uncorrected p-values by the
number of comparisons performed, the reported p-value in
Table 2 becomes almost insignificant, and such marginal p-
values are always expected when a large number of statistical
comparisons are made. Table 3 presents a detailed account of
all genotypic and allelic counts and frequencies that were
observed for each of these clinical subtypes and the three
studied SNPs. Interestingly, when each of these exfoliation
subtypes was compared with the normal controls, a significant
association was detected with all the three LOXL1 SNPs.
Therefore,  as  no  major  allelic  differences  were  observed
between these phenotypic subgroups and as each subtype is
highly associated with the three SNPs, we combined them as
a  single  phenotype  (exfoliation  syndrome,  XFS)  for
subsequent statistical evaluations. The observed genotypic
frequencies in Table 3 were tested for possible deviations from
the  Hardy–Weinberg  Equilibrium  (HWE)  in  both  the
exfoliation and control groups. No deviation was observed
from the HWE expectation for any of these two groups. As
shown in Table 3, all three SNPs are highly associated with
every single one of these clinical subtypes. For the two coding
SNPs, rs1048661 (R141L) and rs3825942 (G153D), the two
genotypes of G/G (p=2.85x10−8 and p=7.44x10−15) and the two
corresponding alleles of G (p=7.74x10−9 and p=3.10x10−17)
are highly overrepresented in the exfoliation cases (XFS) as
compared to the control group. Likewise, for the intronic SNP
of  rs2165241,  genotype  T/T  (p=1.24x10−22)  and  its
corresponding allele T (p=4.85x10−24) are highly associated
with  XFS.  Both  the  genotypic  and  allelic  case-control
association tests for each of these three SNPs and for each
clinical subtype were highly significant (Table 3). We also
performed additional statistical evaluations, tabulated odds
ratios  (OR),  and  population  attributable  risk  percentages
(PAR%)  for  each  of  these  three  SNPs  and  under  various
inherited genetic parameters (Table 4). The allelic PAR%
values  for  rs1048661,  rs3825942,  and  rs2165241  were
estimated as 28%, 58%, and 32%, respectively (Table 4).
These PAR% values represent theoretical estimates for the
excessive  rate  of  XFS  in  the  American  and  European
populations that are due to risk-associated factors in LOXL1
polymorphisms. Therefore, if these specific SNP-associated
risk  factors  are  eliminated,  the  incidence  of  XFS  in  the
population is expected to reduce by these percentages per each
SNP.
LOXL1  risk-associated  haplotypes  in  exfoliation
syndrome:  To  determine  the  combined  effect  of  these
polymorphisms  on  XFS,  we  also  performed  a  series  of
statistical analyses for all possible haplotypes of the three
SNPs. Table 5 summarizes the estimated frequencies of each
haplotype and provides results of association tests between
TABLE 2. COMPARISON OF ALLELIC COUNTS AND THE CORRESPONDING P-VALUES FOR LOXL1 SNP MARKERS OF RS1048661,RS3825942, AND
RS2165241 AND DIFFERENT SUBTYPES OF EXFOLIATION SYNDROME.
Exfoliation subtype Name of SNP Allele types Allele counts Exfoliation subtype
XFG XFU XFS
XFO (n=95) rs1048661 G/T 156/32 p1=0.517* p1=0.780 p1=0.675
rs3825942 G/A 173/15 p2=0.001 p2=0.121 p2=0.034
rs2165241 C/T 51/135 p3=0.504 p3=0.672 p3=0.823
XFG (n=133) rs1048661 G/T 225/39 - p1=0.800 p1=0.724
rs3825942 G/A 260/4 - p2=0.216 p2=0.054
rs2165241 C/T 65/199 - p3=0.301 p3=0.548
XFU (n=59) rs1048661 G/T 96/18 - - p1=0.986
rs3825942 G/A 110/4 - - p2=0.782
rs2165241 C/T 35/83 - - p3=0.494
XFS (n=287) rs1048661 G/T 477/89 - - -
rs3825942 G/A 543/23 - - -
rs2165241 C/T 151/417 - - -
* p1, p2 and p3 are the corresponding p-values for the three LOXL1 SNPs as listed for each exfoliation subtype. These are
uncorrected allelic p-values when two set of exfoliation subtypes are compared together.
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536XFS and controls for each haplotype. For the first two SNPs
(rs1048661, rs3825942), haplotype GG was overrepresented
by 59% in the XFS cases (0.8021) as compared to controls
(0.5030).  This  deviation  was  statistically  significant
(p=1.47x10−27). In contrast, the other two haplotypes of TG
and GA were significantly underrepresented in the XFS cases
(Table 5). The TA haplotype was not observed in the control
samples. Comparison of the two haplotypes of GG and TG
relative to GA had odds ratios of 7.87 (p=1.31x10−22) and 2.62
(p=1.51x10−4), respectively. The two haplotypes of GG and
TG  accounted  for  96%  of  the  XFS  cases,  and  the  GA
haplotype had the lowest estimated risk with an attributable
risk percent (AR%) value of 394.
For the two SNPs, rs1048661 and rs2165241, all four
possible haplotypes were estimated in both cases and controls.
For this pair, only the GT haplotype was prevalent in the XFS
cases (0.7284 versus 0.4362), and this deviation (67%) from
the control group was highly significant (p=1.29x10−24). The
two haplotypes of TC (p=1.14x10−8) and GC (p=2.26x10−11)
were statistically underrepresented in the XFS cases while the
TT  haplotype  did  not  show  any  difference  (p=0.6812)
between the two groups (Table 5). The three haplotypes of
GT, TC, and GC significantly accounted for 99% of the XFS
cases. However, when the GT, TC, and GC haplotypes were
compared relative to TT, the tabulated odds ratios of 2.01
(p=0.228),  0.629  (p=0.436),  and  0.513  (p=0.261),
respectively, were not significant. The GC haplotype had the
highest AR% value of 135.
Likewise, for the last two pairs (rs3825942, rs2165241),
only the GT haplotype was overrepresented in the XFS cases
(p=2.02x10−24).  The  two  haplotypes  of  GC  and  AC  were
significantly underrepresented in the cases. Comparison of the
two  common  haplotypes  of  GT  and  GC  relative  to  AC
produced  odds  ratios  of  8.74  (p=2.51x10−23)  and  3.39
(p=1.08x10−6),  respectively,  and  these  two  haplotypes
accounted  for  96%  of  XFS  cases.  In  summary,  cross
comparisons between each two pairs of SNPs revealed that
the  GG,  GT,  and  GT  haplotypes  were  significantly
overrepresented in the XFS patients. Seven of the other eight
haplotypes were significantly more frequent in the controls.
When we tabulated the combined effect of these three
SNPs  on  XFS,  the  GGT  haplotype  was  significantly
overrepresented  (p=1.93x10−24)  while  the  two  other
haplotypes  of  GAC  and  TGC  were  significantly
underrepresented  (Table  5).  There  were  no  significant
differences between cases and controls for the two haplotypes
of GGC and TGT. The GAT haplotype was not observed. The
combined three haplotypes of GGT, GAC, and TGC were
associated with 91% of the XFS in the study population. When
the three haplotypes of GGT, GAC, and TGC were compared
individually to non-associated haplotypes of GGC or TGT,
the estimated odds ratios of 1.38 (p=0.152) or 1.98 (p=0.240),
TABLE 3. GENOTYPIC AND ALLELIC COUNTS, FREQUENCIES, AND P-VALUES FOR THREE LOXL1 POLYMORPHISMS IN DIFFERENT SUBTYPES OF EXFOLIATION SYNDROME.
Phenotype LOXL1 SNPs rs1048661
(R141L)
rs3825942
(G153D)
rs2165241
Genotypic and allelic p-values were tabulated individually between each of the exfoliation subtypes and controls (n=333).
TABLE 4. ASSOCIATION TESTS, ODDS RATIOS, AND POPULATION ATTRIBUTABLE RISK PERCENT (PAR%) FOR THREE SNPS OF THE LOXL1 GENE.
Genetic test rs1048661
(R141L)
rs3825942
(G153D)
rs2165241
Note that p-values provided under each of these three SNPs were obtained by comparing only the rare genotypes or alleles
against other genotypes or alleles, respectively.
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GG/GT/TT G/T GG/GA/AA G/A CC/CT/TT C/T
XFO
(n=95)
Counts 62/32/0 156/32 79/15/0 173/15 4/43/46 51/135
Frequency 0.660/0.340/0.0 0.830/0.170 0.840/0.160/0.0 0.920/0.080 0.043/0.462/0.495 0.274/0.726
p-Value 1.37x10-3 5.44x10-4 9.18x10-4 1.01x10-4 5.99x10-11 2.30x10−11
XFG
(n=133)
Counts 95/35/2 225/39 128/4/0 260/4 9/47/76 65/199
Frequency 0.720/0.265/0.015 0.852/0.148 0.970/0.030/0.0 0.985/0.015 0.068/0.356/0.576 0.246/0.754
p-Value 1.49x10-5 2.53x10-6 1.21x10-11 5.59x10-13 4.83x10−17 4.17x10-17
XFU
(n=59)
Counts 40/16/1 96/18 53/4/0 110/4 3/29/27 35/83
Frequency 0.702/0.280/0.018 0.842/0.158 0.930/0.070/0.0 0.965/0.035 0.051/0.491/0.458 0.297/0.703
p-Value 8.39x10-3 2.17x10-3 1.25x10-4 1.67x10-5 8.24x10-7 3.28x10-7
XFS
(n=287)
Counts 197/83/3 477/89 260/23/0 543/23 16/119/149 151/417
Frequency 0.696/0.293/0.011 0.843/0.157 0.919/0.081/0.0 0.959/0.041 0.056/0.419/0.525 0.266/0.734
p-Value 2.85x10-8 7.74x10-9 7.44x10-15 3.10x10-17 1.24x10-22 4.85x10-24
Controls
(n=333)
Counts 162/140/28 464/196 216/98/18 530/134 94/174/60 362/294
Frequency 0.491/0.424/0.085 0.703/0.297 0.651/0.295/0.054 0.798/0.202 0.287/0.530/0.183 0.552/0.448
p-Value Odds PAR % p-Value Odds PAR % p-Value Odds PAR %
Homozygote 1.00x10-6 0.088 7 5.00x10-5 0.001 4 5.39X10-22 0.069 38
Heterozygote 3.4x10−5 0.488 14 2.46x10-12 0.195 15 1.11X10-11 0.275 34
Dominant 2.72x10-7 0.421 19 2.31x10-15 0.165 19 6.09x10-19 0.203 54
Recessive 2.89x10-5 0.116 4 7.02x10-5 0.001 3 1.38x10-13 0.149 15
Alleles 7.74x10-9 0.442 28 3.10x10-17 0.168 58 4.85x10-24 0.294 320.15  (p=3.31x10−10)  or  4.68  (p=8.55x10−3),  and  2.34
(p=5.52x10−4) or 1.63 (p=0.410), respectively, were obtained.
When the same three associated haplotypes were individually
compared to the combined haplotypes of GGC or TGT, the
estimated odds ratios of 1.44 (p=0.087), 6.42 (p=3.02x10−10),
and  2.24  (p=6.13x10−4)  were  obtained,  respectively.
Interestingly, the lowest significant risk was associated with
the GAC haplotype (reduced by 83%), which accounted for
the greatest protection against XFS with an AR% associated
value of 457 (Table 5).
In  addition  to  the  abovementioned  case-control
association studies, we also tabulated the odds ratios, AR%,
and population attributable risk percent (PAR%) for each of
these haplotypes. As presented in Table 5, risk reduction (or
risk protection for developing XFS) for highly associated
haplotypes of GA (SNPs 1 and 2), GC (SNPs 1 and 3), AC
(SNPs 2 and 3), and GAC were 394, 135, 430, and 457,
respectively. Once the combined effect of these three SNPs
was considered collectively, this data suggests that the GGT
haplotype is overrepresented by 66% in the affected patients
and therefore, is a major risk factor for XFS. On the contrary,
the GAC haplotype is underrepresented in the cases by 83%
and  therefore,  may  play  a  protective  role  against  the
development of XFS. Table 5 also provides the odds ratios
and the 95% confidence intervals for each haplotype as well
as percentages of theoretical reduction in overall incidence of
exfoliation (PAR%) if the corresponding associated haplotype
is to be eliminated (or elevated) from (or in) the population.
DNA sequencing of LOXL1 in exfoliation syndrome: To
determine the potential effect of LOXL1 mutations in XFS
patients from the population under our study, we directly
sequenced the seven coding exons of this gene in a total of 95
unselected and unrelated affected patients. The results of these
sequencings are presented in Table 6. A total of 14 DNA
variations were observed in this gene of which six were in the
coding  exons  and  eight  were  in  the  adjacent  introns.  In
addition to R141L (rs1048661) and G153D (rs3825942) that
were also used in our association studies, we identified two
novel variations, G240G and V385V, each in 1 out of 95
patients. No other significant differences were observed from
the normal referenced sequence.
DISCUSSION
Recent  genome-wide  association  studies  in  the  Icelandic
population identified multiple SNPs from the lysyl oxidase-
like 1 (LOXL1) gene that were highly associated with XFS and
XFG [19]. The same observations were also made in the
Swedish population [19] and have further been confirmed for
two  other  populations  [22,23].  This  topic  has  also  been
subjected to several commentaries and reviews [24-28].
We studied 620 subjects, 287 exfoliation and 333 healthy
controls  from  American  and  European  populations.  All
patients were genotyped using the SNaPshot Assay for three
SNPs  from  LOXL1  that  were  reported  to  have  strong
associations  with  XFS  in  the  Icelandic  and  Swedish
populations [19]. We also confirmed a strong association with
LOXL1 variants in our patients (Table 3–Table 5). The G
alleles of rs1048661 (SNP 1) and rs3825942 (SNP 2) together
with the T allele of rs2165241 (SNP 3) are highly associated
with  XFS  and  XFG.  When  two-locus  haplotypes  were
tabulated between SNP 1 and SNP 2, the GG haplotype was
overrepresented in the affected cases while the TG and GA
TABLE 5. ESTIMATED TWO- AND THREE-LOCI HAPLOTYPE FREQUENCIES FOR THREE LOXL1 SNPS AND THEIR CORRESPONDING ASSOCIATION TESTS BETWEEN EXFOLIATION
SYNDROME AND CONTROLS.
SNP1 alleles SNP2 alleles XFS Controls Association tests between exfoliation and controls
rs1048661 rs3825942 n=566 n=658 p-Values Odds (95% C.I.) AR% PAR%
G G 0.8021 0.503 1.47x10−27 4.00 (3.10–5.18) 37 22
T G 0.1572 0.2964 9.01x10−9 0.44 (0.33–0.59) 88 28
G A 0.0406 0.2006 4.83x10−17 0.17 (0.11–0.27) 394 58
rs1048661 rs2165241 n=560 n=650 p-Values Odds (95% C.I.) AR% PAR%
G T 0.7284 0.4362 1.29x10−24 3.46 (2.71–4.41) 40 24
T C 0.1499 0.287 1.14x10−8 0.44 (0.33–0.58) 91 28
G C 0.1126 0.2653 2.26x10−11 0.35 (0.26–0.48) 135 36
T T 0.0091 0.0115 0.6812 0.83 (0.26–2.62) 21 9
rs3825942 rs2165241 n=560 n=654 p-Values Odds (95% C.I.) AR% PAR%
G T 0.7364 0.4458 2.02x10−24 3.45 (2.71–4.40) 39 23
G C 0.2266 0.3547 1.16x10−6 0.53 (0.41–0.69) 56 20
A C 0.037 0.1995 1.49x10−17 0.16 (0.10–0.25) 430 60
Combined haplotypes* n=566 n=666 p-Values Odds (95% C.I.) AR% PAR%
GGT 0.7278 0.4382 1.93x10−24 3.43 (2.69–4.36) 40 23
GAC 0.0346 0.1973 4.99x10−18 0.15 (0.09–0.24) 457 60
TGC 0.1486 0.2877 5.82x10−9 0.43 (0.32–0.57) 94 29
GGC 0.0795 0.0661 0.3693 1.22 (0.79–1.88) 17 9
TGT 0.0097 0.0107 0.8595 0.84 (0.26–2.66) 19 8
Individual p-values for each haplotype, odds ratios, 95% confidence intervals, their associated attributable risks percentages
(AR%), and population attributable risks percentages (PAR%) between exfoliation syndrome and controls are provided. * Order
of the alleles are: rs1048661, rs3825942, and rs2165241.
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Comparison of the two haplotypes of GG and TG relative to
GA  had  odds  ratios  of  7.87  (p=1.31x10−22)  and  2.62
(p=1.51x10−4), respectively. The two haplotypes of GG and
TG accounted for 96% of the XFS cases, and this observation
is in full agreement with the original report for the Icelandic
and Swedish populations [19]. Similarly, for each two-set of
SNP,  the  GG,  GT,  and  GT  haplotypes  were  significantly
overrepresented in the XFS patients. Seven of the other eight
haplotypes were significantly more frequent in the control
patients. When the combined effects of these three SNPs were
tabulated,  the  GGT  haplotype  was  significantly
overrepresented while the two haplotypes of GAC and TGC
were  significantly  underrepresented  in  the  XFS  patients
(Table 5). These three haplotypes accounted for 91% of the
XFS cases in the studied population. In summary, for these
three SNPs, the GGT haplotype was overrepresented by 66%
and constituted a major risk haplotype for XFS while the GAC
haplotype was underrepresented by 83% and had the lowest
associated  risk  in  XFS  patients.  DNA  sequencing  of  95
affected patients did not show any mutations in LOXL1 in our
studied population.
LOXL1  belongs  to  a  family  of  extracellular  copper-
requiring enzymes (i.e., LOX, LOXL1–4) that facilitate cross-
linking  of  collagens  and  elastins  through  oxidative
deamination of lysine or hydroxylysine side chains [29]. The
reported LOXL1 risk-associated polymorphisms in XFS [19]
may be a significant finding as this condition is considered to
be a type of elastosis that affect elastic microfibrils. However,
as  the  most  highly  XFS-associated  haplotypes  were  also
present in 44%–50% of our control subjects (Table 5), it is not
clear at this point how these naturally occurring variations
work  individually  or  cooperatively  to  contribute  to  this
phenotype. Since LOXL1 interacts with other proteins [30,
31] such as fibulin-5 (FBLN5) and elastin (ELN), it is likely
that  through  these  protein–protein  interactions  and  their
anticipated common biochemical pathways, the effect of such
polymorphisms on XFS becomes more significant. The two
highly associated SNPs of rs1048661 (R141L; basic arginine
replaced by neutral and hydrophobic leucine) and rs3825942
(G153D; neutral and polar glycine replace by acidic aspartic
acid) are part of the coding region of the LOXL1 protein, and
these two amino acids are highly conserved during evolution.
There is also a strong linkage disequilibrium between these
two SNPs (D’=0.996) thus suggesting that the effect of these
two  amino  acid  polymorphisms  on  XFS  is  probably
influenced  by  protein–protein  interaction  of  LOXL1  with
FBLN5,  ELN,  or  other,  unidentified  LOXL1-interacting
proteins. Identification of specific polymorphisms in LOXL1
that are highly associated with XFS and XFG provide a good
starting point for future research into the etiology of this
condition. Although LOXL1 null mice [32] have not been
specifically reported to have any ocular phenotype resembling
XFS, perhaps the study of such animals at very old stages of
life and/or their cross-breeding with other animals lacking
LOXL1-interacting proteins such as FBLN5 and ELN are now
warranted.  However,  as  LOXL1  polymorphisms  are
frequently seen in normal patients, it is not clear at this point
how such information can provide any immediate assistance
to patients having this condition or being at high risk for
development of XFS or XFG.
It  is  now  possible  to  determine  specific  haplotype
composition  of  LOXL1  polymorphisms  in  an  individual
patient  and  use  the  anticipated  population-related  risk
frequencies to categorize a person into a relatively high or low
risk  group.  However,  it  is  not  clear  at  this  point  if  such
information  should  be  used  to  alter  the  normal  clinical
management  of  an  individual  as  these  risk  estimates  are
relative,  tentative,  conditional,  and  probably  population
specific.  More  importantly,  such  polymorphisms  are  also
Molecular Vision 2008; 14:533-541 <http://www.molvis.org/molvis/v14/a65> © 2008 Molecular Vision
539
TABLE 6. DNA SEQUENCING RESULTS OF 95 PATIENTS WITH EXFOLIATION SYNDROME.
Location Nucleotide change Amino acid
change
SNP number Wildtype homozygous Number of subjects observed with this variant
Heterozygous Homozygous
Exon 1 CGG>CTG R141L rs1048661 61 33 1
GGC>GAC G153D rs3825942 90 5 0
GGC>GGT G240G - 94 1 0
GAC>GAT D292D - 93 2 0
GCG>GCT A320A - 82 12 1
Exon 2 GTG>GTC V385V - 94 1 0
Intron 2 IVS2+197C>T - rs2304719 84 11 0
Intron 3 IVS3+23C>T - - 94 1 0
IVS3–155G>A - - 82 13 0
IVS3–101G>A - - 66 28 0
Intron 4 IVS4+49G>A - - 94 1 0
Intron 5 IVS5+111C>A - rs2304721 79 15 1
IVS5–121C>T - - 88 6 0
IVS5–51T>C - rs2304722 67 28 0
A total of 14 DNA variations were observed in this gene of which six were in the coding exons and eight were in the adjacent
introns.significantly observed in healthy control subjects. Therefore,
it  is  unlikely  that  such  information  will  be  useful  for
immediate day-to-day clinical management of patients.
It  is  also  interesting  that  LOXL1  polymorphisms  are
highly  associated  with  both  XFS  and  XFG,  but  no  such
association  was  reported  for  subjects  only  affected  with
primary open-angle glaucoma [19]. This in turn suggests that
other  factors  must  exist  that  predisposes  an  individual  to
develop glaucoma. Therefore, it is likely that XFG represents
a  group  of  patients  that  were  hereditarily  predisposed  to
glaucoma, but they instead developed XFG either because of
LOXL1 associated polymorphisms impacting the predisposed
glaucoma gene expression and protein function or because of
other as yet unknown systemic, hereditary, or environmental
factors. Further research into the role of the LOXL1 protein
in  the  etiology  of  exfoliation  syndrome  and  exfoliation
glaucoma is urgently needed.
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